Acute heart failure is a sudden medical emergency where the heart loses its ability to pump enough oxygen-rich blood throughout the body, threatening life within hours and requiring immediate hospital intervention to stabilize breathing, reduce fluid overload, and prevent organ damage.

When Every Heartbeat Counts: Understanding Treatment Pathways

Acute heart failure represents one of the most urgent challenges in cardiovascular medicine, where the primary goal of treatment is to rapidly restore the heart’s ability to supply the body with adequate blood and oxygen. Unlike chronic heart failure, which develops gradually over months or years, acute heart failure strikes suddenly—often following a heart attack, severe infection, or rapid worsening of an existing heart condition. The treatment approach focuses on several critical objectives: relieving severe symptoms like breathlessness and fluid accumulation, stabilizing blood pressure and heart rhythm, protecting vital organs from damage, and identifying the underlying trigger that caused the acute episode.^[1]

The management of acute heart failure depends heavily on the patient’s initial condition and the severity of their symptoms. Healthcare providers must quickly assess whether the patient has acute decompensated heart failure, where a pre-existing chronic condition suddenly worsens, or de novo acute heart failure, which occurs in someone with no prior heart disease history. Each situation requires a tailored strategy, as the causes can vary dramatically—from coronary artery disease and valve problems to fluid imbalances and rhythm disturbances. Treatment also considers the patient’s hemodynamic status, meaning whether blood pressure is too high, too low, or unstable, which guides medication choices.^[6]

Medical societies worldwide, including the European Society of Cardiology and the American College of Cardiology, have established clinical guidelines based on extensive research and patient outcomes. These guidelines emphasize early intervention, continuous monitoring, and a multidisciplinary approach involving cardiologists, emergency medicine specialists, and critical care teams. However, despite these standardized protocols, acute heart failure remains associated with high mortality and frequent hospital readmissions. This reality drives ongoing research into novel therapies and improved care strategies, including medications currently being tested in clinical trials that aim to address the underlying mechanisms more effectively than existing treatments.^[3]

Standard Treatment: Stabilizing the Storm

When a patient arrives at the hospital with acute heart failure, immediate treatment begins with oxygen therapy and positioning to ease breathing. Many patients struggle to breathe while lying flat, so sitting upright often provides relief. Healthcare providers administer supplemental oxygen through nasal prongs or masks to ensure adequate oxygen saturation in the blood. In severe cases where breathing becomes critically impaired, non-invasive ventilation or even mechanical ventilation may be necessary to support lung function and prevent complete respiratory failure.^[4]

The cornerstone of acute treatment involves diuretics, medications that help the kidneys remove excess fluid from the body through increased urination. The most commonly used diuretics are furosemide (also called frusemide) and bumetanide, typically given intravenously in the emergency setting to achieve rapid effect. These medications reduce the fluid congestion in the lungs and throughout the body that causes swelling in the legs, ankles, and abdomen. By removing this excess fluid, diuretics help relieve breathlessness and reduce the workload on the failing heart. However, healthcare teams must monitor patients closely, as diuretics can cause dehydration, drops in blood pressure, and imbalances in essential minerals like sodium and potassium.^[13]

In addition to diuretics, many patients receive vasodilators—drugs that relax and widen blood vessels, making it easier for the weakened heart to pump blood forward. These medications reduce the resistance the heart must overcome with each contraction. Vasodilators also help lower blood pressure when it’s elevated, which frequently occurs in acute heart failure. The choice of vasodilator depends on the patient’s blood pressure and overall condition, as these drugs can cause blood pressure to drop too low in some individuals.^[12]

For patients with low blood pressure or signs of inadequate blood flow to vital organs—a condition called hypoperfusion—healthcare providers may use inotropic agents. These are medications that increase the force of the heart’s contractions, helping it pump more effectively. Common inotropic drugs include dobutamine and milrinone. While these medications can be lifesaving in the short term, they must be used cautiously as they increase the heart’s oxygen demand and can provoke dangerous heart rhythm problems. They’re typically reserved for the most severely ill patients and are given through continuous intravenous infusion under intensive monitoring.^[10]

Once the acute crisis begins to stabilize, typically within 24 to 48 hours, physicians transition patients to oral medications designed for longer-term management. These include ACE inhibitors (such as ramipril, lisinopril, or enalapril), which work by blocking a hormone system that puts extra strain on the heart. If patients cannot tolerate ACE inhibitors due to side effects like persistent dry cough, they’re often switched to angiotensin receptor blockers (ARBs), such as candesartan or valsartan, which work similarly but through a different mechanism.^[13]

Beta-blockers form another essential class of medications for heart failure. Drugs like bisoprolol, carvedilol, and nebivolol slow the heart rate and protect the heart muscle from the harmful effects of stress hormones like adrenaline. While beta-blockers are crucial for long-term outcomes, they’re typically started at very low doses and increased gradually, as they can initially worsen symptoms in some patients. Healthcare providers carefully monitor how patients respond before increasing the dose.^[11]

Mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone represent another important medication class. These drugs help remove excess fluid while preserving potassium levels in the blood, unlike standard diuretics which can deplete potassium. MRAs also have beneficial effects on the heart muscle itself, helping to prevent harmful structural changes. Regular blood tests are necessary to monitor potassium levels, as these medications can cause levels to rise dangerously high.^[13]

More recently, a newer class of medications called sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) has been added to standard treatment guidelines. Originally developed for diabetes, these drugs (including dapagliflozin and empagliflozin) have shown remarkable benefits in heart failure patients, whether or not they have diabetes. They help the kidneys remove excess fluid and appear to have protective effects on the heart muscle. Current guidelines now recommend SGLT2 inhibitors for most stabilized heart failure patients regardless of their ejection fraction.^[12]

Treatment duration varies significantly depending on the underlying cause of acute heart failure. Patients who’ve experienced a heart attack may need lifelong medication to prevent further cardiac events. Those whose heart failure resulted from a treatable cause, such as a heart valve problem that can be surgically corrected, may see improvement or even resolution of their condition after the underlying issue is addressed. However, most patients with acute heart failure require ongoing medication and monitoring indefinitely.^[2]

Side effects from heart failure medications are common but manageable. Diuretics frequently cause increased urination, which can be disruptive to daily life, and may lead to mineral imbalances requiring dietary adjustments or supplements. ACE inhibitors can cause persistent dry cough and, rarely, dangerous swelling of the lips and tongue. Beta-blockers may cause fatigue, dizziness, or cold hands and feet. SGLT2 inhibitors can increase the risk of genital yeast infections. Patients experiencing troublesome side effects should never stop medications abruptly without consulting their healthcare provider, as sudden discontinuation can trigger a dangerous worsening of heart failure.^[13]

Treatment in Clinical Trials: Tomorrow’s Hope

Despite advances in standard treatment, acute heart failure continues to have poor outcomes, with many patients experiencing repeat hospitalizations and shortened life expectancy. This harsh reality has driven extensive research into new therapeutic approaches that target the underlying disease processes more precisely. Clinical trials are testing innovative molecules and treatment strategies that may revolutionize how we manage this life-threatening condition.^[6]

One promising area of investigation involves angiotensin receptor-neprilysin inhibitors (ARNIs), with sacubitril/valsartan being the most studied compound. This combination medication works through two mechanisms simultaneously: blocking harmful hormone signals (like ARBs do) while also preventing the breakdown of beneficial natural substances that help blood vessels relax and reduce fluid retention. Early clinical trials have shown that ARNIs may reduce hospitalizations and improve survival more effectively than traditional ACE inhibitors alone. Phase III trials have demonstrated particularly impressive results in patients with reduced ejection fraction, leading to regulatory approval in many countries. Some trials are now exploring whether ARNIs could be started earlier in the acute phase, rather than waiting for stabilization, to potentially improve outcomes further.^[12]

Another innovative approach being tested involves soluble guanylate cyclase stimulators. These medications, such as vericiguat, work by enhancing a natural signaling pathway that helps blood vessels relax and reduces strain on the heart. The mechanism is particularly interesting because it addresses dysfunction that occurs at the cellular level in failing hearts. Phase II trials showed promising effects on reducing heart failure events, and larger Phase III studies have been conducted in patients who remain at high risk despite optimal standard therapy. The goal is to determine whether this class of drugs can fill a treatment gap for patients who continue to deteriorate despite taking multiple conventional medications.^[12]

Researchers are also investigating novel inotropic agents that could strengthen heart contractions without the dangerous side effects of current drugs. Traditional inotropes increase calcium levels in heart muscle cells, which strengthens contractions but also increases oxygen demand and can trigger dangerous arrhythmias. Newer experimental agents, currently in Phase I and Phase II trials, work through different mechanisms—such as increasing the sensitivity of heart muscle proteins to calcium rather than raising calcium levels themselves. These drugs, with code names like omecamtiv mecarbil, aim to improve pumping function while causing fewer rhythm disturbances. Early safety studies have been encouraging, though larger trials are needed to prove they improve long-term outcomes.^[10]

Immunotherapy approaches represent an exciting frontier in heart failure research. Scientists have discovered that inflammation plays a significant role in the progression of heart failure, with the immune system sometimes attacking heart tissue or creating chronic inflammation that damages the heart muscle over time. Clinical trials are testing various anti-inflammatory therapies and immune-modulating drugs to see if calming excessive immune responses can slow or reverse heart failure. Some trials are examining whether medications already approved for rheumatoid arthritis or other inflammatory conditions might benefit heart failure patients. These are primarily Phase II studies trying to determine optimal dosing and identify which patient subgroups might benefit most.^[6]

Gene therapy and cell-based therapies are being explored in specialized research centers, though these remain largely in early-phase trials. One approach involves using genes or stem cells to repair damaged heart muscle or stimulate the growth of new blood vessels in the heart. Another strategy uses genetic techniques to modify how heart muscle cells handle calcium, potentially improving contractile function. These highly experimental approaches are primarily available in the United States and Europe at major academic medical centers, and patient eligibility is very selective—typically limited to those with severe heart failure who haven’t responded to conventional treatments.^[6]

Research into device-based therapies continues to evolve. While not strictly medications, clinical trials are testing improved versions of mechanical circulatory support devices—essentially mechanical pumps that assist or replace heart function. Newer devices are smaller, more durable, and cause fewer complications than earlier generations. Some trials are evaluating whether certain patients might benefit from temporary mechanical support during the acute crisis to give the heart time to recover, rather than committing to permanent device implantation. These trials are conducted at specialized heart failure centers with expertise in advanced mechanical support.^[10]

The eligibility criteria for acute heart failure clinical trials vary widely depending on the study design and the therapy being tested. Generally, patients must have a confirmed diagnosis of acute heart failure with specific features such as reduced ejection fraction below a certain threshold or persistent symptoms despite standard treatment. Many trials exclude patients with certain comorbidities like severe kidney disease, recent major surgery, or active cancer. Age restrictions may apply, though some trials specifically focus on elderly populations. Trials are being conducted globally, with significant activity in the United States, throughout Europe, and increasingly in Asian countries. Patients interested in participating should ask their cardiologist or heart failure specialist about available trials, or search clinical trial registries online.^[6]

It’s important to understand the different phases of clinical trials and what they mean. Phase I trials primarily assess safety in small groups of participants, carefully monitoring for side effects and determining appropriate dosing. Phase II trials expand to larger groups and begin evaluating whether the treatment shows evidence of effectiveness while continuing to monitor safety. Phase III trials involve hundreds or thousands of patients and directly compare the new treatment against current standard care to determine whether it truly improves outcomes like survival, hospitalization rates, or quality of life. The results from these large Phase III studies form the basis for regulatory approval decisions. Preliminary results from early-phase trials may seem promising, but only Phase III trials can definitively prove whether a new treatment should become standard practice.^[10]

Most common treatment methods

• Oxygen therapy and breathing support
  • Supplemental oxygen delivered through nasal prongs or face masks to improve blood oxygen levels
  • Non-invasive ventilation using positive pressure to help breathing in severe cases
  • Mechanical ventilation when respiratory failure occurs and the patient cannot breathe adequately on their own
  • Positioning patients upright to ease breathing and reduce lung congestion
• Diuretic medications
  • Intravenous loop diuretics like furosemide and bumetanide to rapidly remove excess fluid from the body
  • Transition to oral diuretics once the patient stabilizes for ongoing fluid management
  • Mineralocorticoid receptor antagonists (spironolactone, eplerenone) that remove fluid while preserving potassium
  • Careful monitoring of kidney function and electrolyte levels during diuretic therapy
• Vasodilator therapy
  • Intravenous vasodilators to relax blood vessels and reduce the heart’s workload during acute episodes
  • Blood pressure management to optimize cardiac function without causing dangerous drops in pressure
  • Nitrate medications to dilate blood vessels and improve blood flow
• Inotropic support
  • Dobutamine and milrinone to strengthen heart contractions in severely ill patients with low blood pressure
  • Continuous intravenous infusion under intensive cardiac monitoring
  • Reserved for cases with cardiogenic shock or severe hypoperfusion of vital organs
• Long-term oral medications
  • ACE inhibitors (ramipril, lisinopril, enalapril) to block harmful hormone systems and reduce heart strain
  • Angiotensin receptor blockers (candesartan, losartan, valsartan) as alternatives when ACE inhibitors aren’t tolerated
  • Beta-blockers (bisoprolol, carvedilol, nebivolol) to slow heart rate and protect from stress hormones
  • SGLT2 inhibitors (dapagliflozin, empagliflozin) to remove fluid and protect heart muscle
  • Angiotensin receptor-neprilysin inhibitors (sacubitril/valsartan) combining multiple beneficial mechanisms
• Treating underlying causes
  • Emergency coronary angioplasty and stenting for acute heart attacks triggering heart failure
  • Heart valve repair or replacement surgery when valve disease causes acute decompensation
  • Electrical cardioversion or medications to restore normal heart rhythm in atrial fibrillation
  • Antibiotics for infections triggering acute episodes
  • Managing hypertension, diabetes, and kidney disease that contribute to heart failure
• Mechanical circulatory support
  • Temporary mechanical pumps to support heart function during severe cardiogenic shock
  • Ventricular assist devices for patients with refractory heart failure awaiting transplant
  • Extracorporeal membrane oxygenation (ECMO) in life-threatening situations
• Investigational therapies in clinical trials
  • Novel inotropic agents with improved safety profiles currently in Phase II and III trials
  • Soluble guanylate cyclase stimulators like vericiguat for patients at continued high risk
  • Anti-inflammatory and immunomodulatory therapies targeting disease mechanisms
  • Gene therapy and stem cell approaches in early-phase studies at specialized centers